|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 85.20 HKD | +1.85% |
|
-7.39% | +132.79% |
| Capitalization | 13TCr 15TCr 1.88TCr 1.6TCr 1.49TCr 1.4TCr 2.59TCr 1,69900Cr 2.82TCr 17TCr 6.76TCr 80TCr 7.04TCr 6.89TCr 2,92200Cr | P/E ratio 2025 * |
78.6x | P/E ratio 2026 * | 43.2x |
|---|---|---|---|---|---|
| Enterprise value | 12TCr 14TCr 1.74TCr 1.48TCr 1.38TCr 1.3TCr 2.4TCr 1,57500Cr 2.62TCr 16TCr 6.26TCr 74TCr 6.52TCr 6.39TCr 2,70800Cr | EV / Sales 2025 * |
9.37x | EV / Sales 2026 * | 7.01x |
| Free-Float |
93.21% | Yield 2025 * |
-
| Yield 2026 * | 0.02% |
Last Transcript: Innovent Biologics, Inc.
| 1 day | +1.85% | ||
| 1 week | -7.39% | ||
| Current month | -9.46% | ||
| 1 month | -7.34% | ||
| 3 months | -12.93% | ||
| 6 months | +5.58% | ||
| Current year | +132.79% |
| 1 week | 82.65 |  | 93.15 |
| 1 month | 82.65 | | 99 |
| Current year | 28.65 | | 109.1 |
| 1 year | 28.65 | | 109.1 |
| 3 years | 27.3 | | 109.1 |
| 5 years | 18.06 | | 109.1 |
| 10 years | 14 | | 109.1 |
| Manager | Title | Age | Since |
|---|---|---|---|
De Chao Yu
CEO | Chief Executive Officer | 61 | 28/04/2011 |
Fei You
DFI | Director of Finance/CFO | 46 | 05/02/2024 |
Ghang Shou Gao
CTO | Chief Tech/Sci/R&D Officer | - | 01/11/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
De Chao Yu
CHM | Chairman | 61 | 28/04/2011 |
Charles Cooney
BRD | Director/Board Member | 80 | 18/10/2015 |
Hao Xi Ede
BRD | Director/Board Member | 66 | 04/06/2018 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 1.78% | 0 M€ | -19.71% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +1.85% | -7.39% | +127.81% | +163.37% | 1.88TCr | |
| -0.74% | +3.19% | +1.37% | -0.84% | 7.61TCr | |
| +2.86% | -0.09% | -33.73% | -38.08% | 5.89TCr | |
| +1.38% | +69.20% | +69.20% | +69.20% | 5.3TCr | |
| -2.24% | -4.93% | +30.25% | +221.80% | 5.25TCr | |
| +0.93% | -3.97% | +16.04% | -40.22% | 2.55TCr | |
| -0.72% | -6.94% | +39.18% | +15.08% | 1.87TCr | |
| -4.52% | -5.15% | +36.59% | +1,036.48% | 1.57TCr | |
| +1.46% | +2.05% | +173.37% | +704.60% | 1.45TCr | |
| -0.04% | -.--% | +58.82% | +142.19% | 1.4TCr | |
| Average | +0.02% | -1.97% | +51.89% | +227.36% | 3.48TCr | |
| Weighted average by Cap. | +0.18% | -0.70% | +31.13% | +125.88% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 1.31TCr 1.44TCr 185.5Cr 158.03Cr 147.62Cr 138.89Cr 255.7Cr 17TCr 279.35Cr 1.72TCr 668.34Cr 7.92TCr 696.04Cr 681.37Cr 29TCr | 1.72TCr 1.89TCr 243.4Cr 207.35Cr 193.69Cr 182.24Cr 335.51Cr 22TCr 366.53Cr 2.26TCr 876.94Cr 10TCr 913.28Cr 894.03Cr 38TCr |
| Net income | 167.59Cr 184.9Cr 24Cr 20Cr 19Cr 18Cr 33Cr 2.15TCr 36Cr 220.63Cr 86Cr 1.01TCr 89Cr 87Cr 3.7TCr | 307.29Cr 339.04Cr 44Cr 37Cr 35Cr 33Cr 60Cr 3.95TCr 66Cr 404.56Cr 156.93Cr 1.86TCr 163.43Cr 159.98Cr 6.78TCr |
| Net Debt | -967.24Cr -1.07TCr -137.1Cr -116.79Cr -109.1Cr -102.65Cr -188.98Cr -12TCr -206.46Cr -1.27TCr -493.95Cr -5.85TCr -514.42Cr -503.58Cr -21TCr | -1.19TCr -1.32TCr -168.97Cr -143.94Cr -134.46Cr -126.51Cr -232.91Cr -15TCr -254.45Cr -1.57TCr -608.78Cr -7.21TCr -634.01Cr -620.64Cr -26TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/25/12 | 85.20 $ | +1.85% | 1,01,84,970 |
| 11/25/11 | 83.65 $ | +0.18% | 86,46,635 |
| 10/25/10 | 83.50 $ | -1.07% | 1,02,85,260 |
| 09/25/09 | 84.40 $ | -1.40% | 2,00,02,920 |
| 08/25/08 | 85.60 $ | -6.96% | 5,26,58,030 |
Delayed Quote Hong Kong S.E., December 12, 2025 at 01:38 pm IST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 1801 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition